DDInter1676 DDInter1949
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]
Voxelotor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Voxelotor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betamethasone
Voxelotor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Voxelotor {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Voxelotor may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone
Voxelotor may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Voxelotor may lead to a major life threatening interaction when taken with Apalutamide